LENSAR, Inc. (LNSR) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$5.59

From 52W high−53.34%

Volume76079.00

Market cap$72.98M

P/E (TTM)4.7x

P/S (TTM)1.2x

Div yield—

Key dataNov 4, 2026

Open

$5.59

From 52W high

−53.34%

Volume

76079.00

Market cap

$72.98M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.7x

P/E (TTM)

4.7x

RSI (14)

31.8

MomentumView details →

1D Return

+6.64%

YTD Return

−51.59%

SummaryUpdated Jun 1, 2026

LENSAR, Inc. (NASDAQ:LNSR) is a commercial-stage medical device company founded in 2004 and headquartered in Orlando, Florida. The company went public in October 2020 and specializes in developing femtosecond laser systems for cataract surgery and corneal astigmatism management. LENSAR has established itself as a significant player in the laser-assisted cataract surgery market, with approximately 21% market share in the United States and over 385 systems installed globally as of 2024.

Ask drillr about LENSAR, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

4.7x

EV/EBITDA

1.7x

EV/Sales

1.0x

P/S (TTM)

1.2x

P/B (TTM)

4.9x

ProfitabilityView details →

Gross Margin

47.96%

Net Margin

57.57%

EBITDA Margin

60.51%

ROE (TTM)

232.78%

ROA (TTM)

49.88%

Asset Turnover

0.89x

GrowthView details →

Revenue YoY

+3.26%

EPS YoY

+130.17%

FCF YoY

−40.06%

Revenue CAGR 3Y

+18.23%

EPS CAGR 3Y

−5.13%

EBITDA YoY

+233.27%

MomentumView details →

1D Return

+6.64%

YTD Return

−51.59%

1Y Return

−55.03%

RSI (14)

31.8

vs 50D SMA

−18.43%

vs 200D SMA

−23.49%

Capital & dividendView details →

Debt/Equity

0.16x

Current Ratio

2.39x

Quick Ratio

1.13x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.10

EPS Surprise

160.61%

Beats (12Q)

5/12

Next Q EPS Est

−$0.07

Avg Surprise (4Q)

153.28%

Rev Surprise

−6.58%

Financials snapshotView financials →

Revenue (TTM)

60.26M

Net Income (TTM)

34.70M

Op. CF (TTM)

−7.29M

Next earningsNov 10, 2026 →

Latest newsMore news →

LENSAR, Inc. announced that it will release its third-quarter 2026 financial results before market open on November 10, 2026.1d ago

LENSAR, Inc. reported its financial results for the second quarter of 2026, with recurring revenue of $13.7 million and 10 ALLY Robotic Cataract Laser System placements, bringing the total laser installed base to 445 systems.83d ago

Similar companies

electroCore, Inc.ECOR Hyperfine, Inc.HYPR Outset Medical, Inc.OM Lucid Diagnostics Inc.LUCD Vivani Medical, Inc.VANI Envoy Medical, Inc.COCH Find similar companies →

Latest newsMore news →

LENSAR, Inc. announced that it will release its third-quarter 2026 financial results before market open on November 10, 2026.1d ago LENSAR, Inc. reported its financial results for the second quarter of 2026, with recurring revenue of $13.7 million and 10 ALLY Robotic Cataract Laser System placements, bringing the total laser installed base to 445 systems.83d ago